Diversifying funding for research and development
First written in FY2024. 6 of 7 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-08-14.
91 other companies' latest entry also says "Advanced".
- 2026-08-14AdvancedOccurring Fact
「The factors contributing to other operating income included ¥52.000 million in grant income resulting from the confirmation of a grant under a project adopted by the Japan Agency for Medical Research and Development (AMED) (the "AMED") under its Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy, as well as ¥12.747 million in foreign exchange gains resulting from the revaluation of foreign-currency-denominated assets.」
With respect to grants, one source of research and development funding, the Company confirmed a ¥52.000 million grant under an AMED project and recognized it as income. - FY2027-H1AdvancedAnnual report
「The main component was ¥22,492 thousand in proceeds from the issuance of shares through the exercise of stock acquisition rights.」
The Company issued shares upon exercise of stock acquisition rights and received ¥22,492 thousand. This existing equity funding method for R&D was also used during the interim accounting period. - 2026-05-15AdvancedRevision to earnings forecast
「During the cumulative first-quarter period, capital stock and capital surplus each increased by ¥5.215 million as a result of the exercise of stock acquisition rights.」
The Company disclosed that it had raised funds through the issuance of shares following the exercise of stock acquisition rights. - FY2025AdvancedAnnual report
「Proceeds from the issuance of shares through the exercise of stock acquisition rights ¥381,053 thousand」
The Company raised ¥381,053 thousand through the issuance of shares upon exercise of stock acquisition rights, securing R&D funding through equity. - 2026-03-06AdvancedGeneral Meetings of Shareholders
「During the fiscal year, we raised ¥381 million through the issuance of new shares upon the exercise of stock acquisition rights.」
The Company raised funds for research and development and other purposes by issuing shares following the exercise of stock acquisition rights. - FY2026-H1AdvancedAnnual report
「Proceeds from the issuance of shares through the exercise of stock acquisition rights ¥201,592 thousand」
The Company raised ¥201,592 thousand through the issuance of shares upon exercise of stock acquisition rights, securing R&D funding through equity. - FY2024First statedAnnual report
「Alongside further business advancement, we will diversify funding sources for R&D through not only the equity markets but also bank loans, subsidies and other means, thereby strengthening our financial base.」
The Company is diversifying R&D funding sources by combining an exchange listing, public offerings, bank loans, subsidies and milestone payments from partners.